The increased intestinal absorption rate is responsible for the reduced hepatic first-pass extraction of propranolol in rats with cisplatin-induced renal dysfunction

Journal of Pharmacy and Pharmacology

Volumn 55, Issue 4, 2003, Pages 479-486

  Okabe, Hiromi ^a   Mizukami, Akiko ^a   Taguchi, Masato ^a   Aiba, Tetsuya ^a   Yasuhara, Masato ^b   Hashimoto, Yukiya ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GLYCEROL; PROPRANOLOL;

ACUTE KIDNEY FAILURE; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE KIDNEY FUNCTION RELATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG INFUSION; DRUG MECHANISM; FIRST PASS EFFECT; INTESTINE ABSORPTION; KIDNEY DYSFUNCTION; LIVER METABOLISM; MALE; NONHUMAN; RAT; RAT STRAIN;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; BIOLOGICAL AVAILABILITY; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; INTESTINAL ABSORPTION; KIDNEY DISEASES; LIVER; MALE; PROPRANOLOL; RATS; RATS, WISTAR;

EID: 0037723944     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/002235702982     Document Type: Article

References (30)

1. Balant, L., Francis, R. J., Tozer, T. N., Marmy, A., Tschopp, J. M., Farbe, J. (1980) Influence of renal failure on the hepatic clearence of bufralol in man. J. Pharmacokinet. Biopharm. 8: 421-438
2. Beal, S. L., Sheiner L B. (1992) NONMEM Users Guide. Universtiy of California, San Francisco
3. Bianchetti, G., Graziani, G., Brancaccio, D., Morganti, A., Leonetti, G., Manfrin, M., Sega, R., Gomeni, R., Ponticelli, C., Morselli, P. L. (1976) Pharmacokinetics and effects of propranolol in terminal uraemic patients and in patients undergoing regular dialysis treatment. Clin. Pharmacokinet. 1: 373-384
4. Chau, N. P., Weiss, Y. A., Safar, M. E., Lavene, D. E., Georges, D. R., Milliez, P. L. (1977) Pindolol availability in hypertensive patients with normal and impaired renal fucntion. Clin. Pharmacol. Ther. 22: 505-510
5. Dayer, P., Balanti, L., Kupfer, A., Striberni, R., Leemann, T. (1985) Effect of oxidative polymorphism (debrisoquine/sparteine type) on hepatic first-pass metabolism of bufuralol. Eur. J. Clin. Pharmacol. 28: 317-320
6. Gibaldi, M., Feldman, S. (1969) Pharmacokinetic basis for the influence of route of administration on the area under the plasma concentration-time curve. J. Pharm. Sci. 58: 1477-1480
7. Hashimoto, Y., Aiba, T., Yasuhara, M., Hori, R. (2001) Effect of experimental renal dysfunction on bioavailability of ajmaline in rats. J. Pharm. Pharmacol. 53: 805-813
8. Hori, R., Okumura, K., Yasuhara, M., Katayamao, H. (1985) Reduced hepatic uptake of propranolol in rats with acute renal failure. Biochem. Pharmacol. 34: 2679-2683
9. Huang, J., Chuang, S., Cheng, C., Lai M. (1999) Pharmacokinetics of metoprolol enantiomers in Chinese subjects of major CYP2D6 genotypes. Clin. Pharmacol. Ther. 65: 402-407
10. Huang, Z., Murakami, T., Okochi, A., Yumoto, R., Nagai, J., Takano, M. (2000) Expression and function of P-glycoprotein in rats with glycerol-induced acute renal failure. Eur. J. Pharmacol. 406: 453-460
11. Jordo, L., Atmam, P. O., Aurell, M., Johansson, L., Johnsson, G. Regardh, C. G. (1980) Pharmacokinetics and pharmacodynamic properties of metoprolol in patients with impaired renal function. Clin. Pharmacokinet. 5: 169-180
12. Katayama, H., Fujiwara, J., Yasuhara, M., Okumura, K., Hori, R. (1984) Increased availability of propranolol in rats with uranyl nitrate-induced acute renal failure. J. Pharm. Dyn. 7: 536-544
13. Kimura, T., Ikeda, K., Kobayashi, A., Nakayama, T. (1984) Effect of experimental acute renal failure on intestinal barriers to drug absorption. Chem. Pharm. Bull. 32: 2471-2473
14. Kimura, T., Kobayashio, A., Kobayashi, M., Numata, K., KAwai Y., Nakayama, T., Mori, M., Awai, M. (1988) Intestinal absorption of drugs in rats with glycerol-induced acute renal failure. Chem. Pharm. Bull. 36: 1847-1856
15. Laganiere, S., Shen, D. D. (1987) Altered S(-)-propranolol disposition in bilateral ureter-ligated rats. Nephron 46: 305-311
16. Loo, J. C. K., Riegelman, S. (1968) New method for calculating the intrinsic absorption rate of drugs. J. Pharm. Sci. 57: 918-928
17. Magnusson, M., Magnusson, K., Sundqvist, T., Dennneberg, T. (1991) Impaired intestinal barrier function measured by differently sized polyethylene glycols in patients with chronic renal failure. Gut 32: 754-759
18. Masubuchi, Y., Hosokawa, S., Horie, T., Suzuki, T., Ohmori, S., Kitada, M., Narimatu, S. (1994) Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase. Drug Metab. Dispos. 22: 909-915
19. Okabe, H., Hashimoto, Y., Inui, K. (2000) Pharmacokinetics and bioavailability of tacrolimus in rats with experimental renal dysfunction. J. Pharm. Pharmacol. 52: 1467-1472
20. Okabe, H., Yano, I., Hashimoto, Y., Saito, H., Inui, K. (2002) Evaluation of increased bioavailability of tacrolimus in rats with experimental renal dysfunction. J. Pharm. Pharmacol. 54: 65-70
21. Padrini, R., Iovan, D., Javarnaro, A., Cucchini, F., Ferrari, M. (1993) Pharmacokinetics and electrophysiological effects of intravenous ajmaline. Clin Pharmacokinet. 25: 408-414
22. Shand, D. G., Rangno, R. E. (1972) The disposition of propranolol. I. Elimination during oral absorption in man. Pharmacology 7: 159-168
23. Suzuki, T., Ohkuma, T., Isozaki, S. (1981) Nonlinear first-pass metabolism of propranolol in the rat. J. Pharm. Dyn. 4: 131-141
24. Terao, N., Shen, D. D. (1983) Effect of experimental renal failure on the disposition kinetics of l-propranolol in rats. J Pharmacol. Exp. Ther. 227: 295-301
25. Terao, N., Shen, D. D. (1984) Pharmacokinetics of l-propranolol during repetitive dosing in normal and uranyl nitrate-induced renal failure rats. J. Pharmacokinet. Biopharm. 12: 479-493
26. Terao, N., Shen, D. D. (1985) Reduced extraction of l-propranolol by perfused rat liver in the presence of uremic blood. J. Pharmacol. Exp. Ther. 233; 277-284
27. Walle, T., Conradi, E. C., Walle, U. K., Fagan, T. C., Gaffney, T. E. (1978) The predictable relationship between plasma levels and dose during chronic propranolol therapy. Clin Pharmacol. Ther. 24: 668-677
28. Yamada, K., Yatsuzuka, A., Yasuhara, M., Okumura, K., Hori, R., Sakurai, T., Kawai, C. (1986) Mechanics of pharmacokinetic interaction between ajmaline and quinidine in rats. J. Pharmacobio-Dyn. 9: 347-351
29. Yasuhara, M., Fujiwara, J., Kitada, S., Katayama, H., Okumura, K., Hori, R. (1985) Effect of altered plasma protein binding on pharmacokinetics and pharmacodynamics of propranolol in rats after surgery: Role of alpha-1-acid glycoprotein. J. Pharmacol. Exp. Ther. 235: 513-520
30. Zekorn, C., Achtert, G., Hausleiter, H. J., Moon, C. H., Eichelbaum, M. (1985) Pharmacokinetics of N-propylajmaline in relation to polymorphic sparteine oxidation. Klin. Wochenschr. 15: 1180-1186